Avidity Biosciences is a biotechnology company focused on developing a new class of targeted RNA therapeutics to improve the lives of people with serious diseases. Its approach centers on Antibody Oligonucleotide Conjugates (AOCs), an investigational platform that combines the targeting specificity of monoclonal antibodies with the precision of oligonucleotides. By integrating these technologies, Avidity aims to deliver RNA-based medicines to tissue and cell types that have been difficult to reach and address genetic drivers at the root of disease.

The company’s programs begin with a muscle disease franchise and include clinical development efforts for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). These are investigational therapies, not established treatments. Avidity advances its pipeline with the goal of creating potential treatment options for patients and their families.

The company also provides information for patients and healthcare professionals, including disease and trial resources, publications, expanded access information, and a channel for medical inquiries.